PHESGO 600mg/600mg/ 20000 units /10ml Price

Overview

Welcome to Dwaey, specifically on PHESGO 600mg/600mg/ 20000 units /10ml Solution for Injection page.
This medicine contains an important and useful components, as it consists of Trastuzumab/ Pertuzumab/ Hyaluronidase.
PHESGO 600mg/600mg/ 20000 units /10ml is available in the market in concentration 600mg/600mg/ 20000 units /10ml and in the form of Solution for Injection.

F. HOFFMANN-LA ROCHE LTD is the producer of PHESGO 600mg/600mg/ 20000 units /10ml and it is imported from SWITZERLAND, The most popular alternatives of PHESGO 600mg/600mg/ 20000 units /10ml are listed downward .

Mode Of Action

Trastuzumab, a monoclonal antibody, has action directed against a cell surface protein produced by human epidermal growth factor receptor 2 (HER2). It inhibits proliferation of tumour cells that overexpress HER2 e.g. in 1/3 of breast cancer.

Indication

• Breast cancer
• Gastric cancer

Precaution

Patient w/ pre-existing CV and pulmonary disease; extensive pulmonary tumour involvement. Pregnancy and lactation. Monitoring Parameters Monitor cardiac function prior and during treatment. Lactation: not known if excreted in breast milk, discontinue nursing during treatment and for 6 months after last dose

Side Effects

• >10% Pain (47%)
• Asthenia (42%)
• Fever (36%)
• Nausea (33%)
• Chills (32%)
• Cough (26%)
• Headache (26%)
• Diarrhea (25%)
• Vomiting (23%)
• Abdominal pain (22%)
• Back pain (22%)
• Dyspnea (22%)
• Infection (20%)
• Rash (18%)
• Anorexia (14%)
• Insomnia (14%)
• Dizziness (13%) 1-10% Flu-like syndrome (10%)
• Peripheral edema (10%)
• CHF (7%)
• Depression (6%)
• Tachycardia (5%)
• UTI (5%)
• Anemia (4%)
• Hypersensitivity (3%)
• Leukopenia (3%) Potentially Fatal: Severe hypersensitivity (anaphylaxis) and infusion reactions; pulmonary events e.g. acute respiratory distress syndrome; cardiotoxicity. Neutropenia (especially when given with chemotherapy).

Contra indication

Lactation (start only 6 mth after last dose of drug). Do not admin by rapid IV or bolus inj.

Pregnancy and lactation

Pregnancy category: D

There is positive evidence of human fetal risk based on adverse reaction data from investigational or marketing experience or studies in humans, but potential benefits may warrant use of the drug in pregnant women despite potential risks.